Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Kintor Pharmaceutical-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostic Technology, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for this project will not exceed RMB 370 million, aimed at constructing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Core Viewpoint - Kintor Pharmaceutical (02171.HK) has signed a strategic cooperation agreement with Shanghai Jinkong Enterprise Development to invest up to 370 million yuan in building a CAR-T cell therapy product commercialization production base in Shanghai's Jinshan District, aligning with the commercialization process of multiple CAR-T products [1][2]. Group 1: Investment and Production Base - The total investment for the new CAR-T drug production base is capped at 370 million yuan, with the construction managed by Shanghai Jinkong [1]. - The investment will be executed through a phased payment model, allowing Kintor to retain cash flow for core R&D and new drug promotion [3]. - The construction is expected to take 14 months, with Kintor making quarterly service fee payments during the initial years [3]. Group 2: Product Development and Market Potential - Kintor's CAR-T product, Shurui Kiorunai, is currently under review for market approval and is the first entity-targeting CAR-T product to submit a New Drug Application in China [2]. - The product targets Claudin18.2 positive advanced gastric/esophageal junction adenocarcinoma, with clinical trial results showing superior efficacy compared to existing therapies [2]. - The market for gastric cancer treatment is significant, with 358,700 new cases and 260,400 deaths reported in 2022 in China, indicating a high demand for effective therapies [2]. Group 3: Financial Performance - Kintor expects a significant reduction in net losses, projecting a loss of no more than 120 million yuan for the reporting period, down from 798 million yuan in the previous year [4]. - The reduction in losses is attributed to increased commercialization revenue from the existing product, Zewokiorunai, and decreased R&D expenditures for both Zewokiorunai and Shurui Kiorunai [4]. - As of June 30, 2025, Kintor reported cash and bank balances of approximately 1.261 billion yuan, indicating sufficient cash flow until 2028 without considering future inflows [3].

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building a commercial production base for advanced CAR-T cell therapy products in Shanghai, aligning with its commercialization efforts for multiple CAR-T therapies [1] Group 1: Investment and Strategic Partnership - The investment will be made through the company's wholly-owned subsidiary, Shanghai Kaixing Diagnostic Technology Co., Ltd., in collaboration with Shanghai Jinguang Enterprise Development Co., Ltd. [1] - The total investment amount is capped at RMB 370 million, indicating a significant commitment to expanding production capabilities [1] Group 2: Product Development and Commercialization - The new production base will support the commercialization of several CAR-T cell therapy products, including the already launched product, Sai Kaize®, and the product under new drug application, CT041 (proposed brand name "Kailimei") [1] - The initiative aims to lay the groundwork for future mass production of various universal CAR-T cell therapy products, such as CT0596 and CT1190B [1] Group 3: Operational and Financial Strategy - The transaction allows the company to avoid large capital expenditures initially, preserving cash flow for core research and market expansion [1] - A buyback mechanism is in place to ensure the company can gain complete control of the assets after long-term operations, maintaining production stability and enhancing asset layout flexibility [1]

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building an advanced CAR-T cell therapy product commercialization production base in Shanghai, aligning with its commercialization process for multiple CAR-T products [1] Group 1: Investment and Development - The total investment for the new production base is capped at RMB 370 million, which will support the commercialization of existing and upcoming CAR-T cell therapy products [1] - The production base will facilitate the commercialization of the already launched product, Sai Kaize, and the new drug application stage product, Shu Ru Ji Ao Lun Sai injection (tentative name: Kai Li Mei TM) [1] - The investment strategy allows the company to avoid significant capital expenditures early on, preserving cash flow for core R&D and market expansion [1] Group 2: Strategic Importance - The collaboration is seen as a core initiative to enhance CAR-T cell therapy production capacity that meets international standards, crucial for the commercialization of multiple products and strengthening global competitiveness [1] - The agreement reflects the company's robust financial planning and deep engagement in the CAR-T cell therapy industry ecosystem, aligning with national and local biopharmaceutical industry policies [1] - This strategic partnership is expected to solidify the company's leading position in the global CAR-T cell therapy field and create long-term value for shareholders [1]

Core Viewpoint - The strategic cooperation agreement signed by the company with Shanghai Jinguang Enterprise Development involves an investment of up to RMB 370 million to establish a commercial production base for advanced CAR-T cell therapy products in Shanghai [1][2] Group 1: Investment and Development - The investment will support the commercialization process of multiple CAR-T cell therapy products, including the already launched product, Sai Kaize®, and the product Shurijiaolun Sai injection (proposed brand name: KailimeiTM), which is in the new drug application stage [1] - The establishment of the production base is aimed at enhancing the capacity for CAR-T cell therapy products that meet international standards, which is crucial for the commercialization of various products and strengthening global competitiveness [1] Group 2: Financial Strategy and Government Support - The transaction allows the company to avoid significant early capital expenditures, preserving valuable cash flow for core research and market expansion [1] - The strategic cooperation reflects the company's robust financial planning and deep integration into the CAR-T cell therapy industry ecosystem, aligning with national and local biopharmaceutical industry policies, receiving strong government support [2] - This collaboration is expected to further solidify the company's leading position in the global CAR-T cell therapy field and create long-term value for shareholders [2]

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 須予披露交易— 訂立戰略合作協議 戰略合作協議 董事會欣然宣佈，於2026年2月12日（交易時段後）科濟藥業控股有限公司透 過其間接全資附屬公司上海愷興診斷技術，與上海市金山區灣區高新區的重要 平台企業——上海金工企業發展簽署戰略合作協議，總投資額不超過人民幣 37,000萬元，將在上海市金山區建設先進的CAR-T細胞治療產品商業化生產基 地。此舉緊密配合本公司多款CAR-T細胞治療產品的商業化進程，包括已上市 的賽愷澤®及處於新藥上市申請階段的實體瘤CAR-T細胞治療產品舒瑞基奧侖 賽注射液（擬定商品名：愷力美TM），並為多款通用型CAR-T細胞治療產品（如 CT0596、CT1190B等）的未來量產奠定基礎。在此背景下，提升符合國際標準 的CAR-T細胞治療產能成為支撐多個產品商業 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | 本月 ...

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]